Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00287183 | 6-Month Safety And Efficacy Study Of TTP488 In Patients With Type 2 Diabetes And Persistent Albuminuria | PHASE2 | COMPLETED | 110 | — | — | Feb 1, 2006 | Aug 1, 2009 | Oct 1, 2009 | 19 | Canada |
| Arm | Type | Description |
|---|---|---|
| PF-04494700 (TTP488) | ACTIVE_COMPARATOR | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PF-04494700 (TTP488) | DRUG | 60 mg/day for 6 days followed by 20 mg/day for 175 days vs placebo, oral medication |
| Placebo | OTHER | Placebo |
Inclusion Criteria: * Male or female outpatients 31 years of age or older. * Females must no longer be of child-bearing potential, must have a negative serum pregnancy test, and cannot be breast-feeding. * Non-vasectomized male must be willing to abstain from sexual intercourse or willing to use a ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | ALN-ANG3, Evinacumab |
| DexCom, Inc. | DXCM | 1 | PHASE3 | Sotagliflozin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | Atrasentan |
| ProKidney Corp. Class A | PROK | 2 | — | Renal Autologous Cell Therapy |